292 related articles for article (PubMed ID: 25752522)
1. Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases.
Stremitzer S; Sunakawa Y; Zhang W; Yang D; Ning Y; Stintzing S; Sebio A; Yamauchi S; Matsusaka S; El-Khoueiry R; Stift J; Wrba F; Gruenberger T; Lenz HJ
Pharmacogenomics J; 2015 Dec; 15(6):521-9. PubMed ID: 25752522
[TBL] [Abstract][Full Text] [Related]
2. Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases.
Stremitzer S; Zhang W; Yang D; Ning Y; Stintzing S; Sunakawa Y; Sebio A; Yamauchi S; Matsusaka S; Parekh A; Barzi A; El-Khoueiry R; Stift J; Wrba F; Gruenberger T; Lenz HJ
Ann Oncol; 2015 Aug; 26(8):1728-33. PubMed ID: 25957329
[TBL] [Abstract][Full Text] [Related]
3. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
[TBL] [Abstract][Full Text] [Related]
4. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.
Pietrantonio F; Mazzaferro V; Miceli R; Cotsoglou C; Melotti F; Fanetti G; Perrone F; Biondani P; Muscarà C; Di Bartolomeo M; Coppa J; Maggi C; Milione M; Tamborini E; de Braud F
Med Oncol; 2015 Jul; 32(7):182. PubMed ID: 26003673
[TBL] [Abstract][Full Text] [Related]
5. Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases.
Stremitzer S; Vermeulen P; Graver S; Kockx M; Dirix L; Yang D; Zhang W; Stift J; Wrba F; Gruenberger T; Lenz HJ; Scherer SJ
Br J Cancer; 2020 May; 122(10):1518-1524. PubMed ID: 32205863
[TBL] [Abstract][Full Text] [Related]
6. Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.
Ichida H; Mise Y; Ito H; Ishizawa T; Inoue Y; Takahashi Y; Shinozaki E; Yamaguchi K; Saiura A
World J Surg Oncol; 2019 Jun; 17(1):100. PubMed ID: 31196104
[TBL] [Abstract][Full Text] [Related]
7. CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Graf A; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Ann Surg Oncol; 2015 Apr; 22(4):1315-23. PubMed ID: 25323471
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first.
Lim C; Doussot A; Osseis M; Esposito F; Salloum C; Calderaro J; Tournigand C; Azoulay D
Clin Transl Oncol; 2018 Oct; 20(10):1274-1279. PubMed ID: 29594943
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases.
García-Alfonso P; Cavanagh Podesta M; Muñoz Martín A; Blanco Codeisido M; Calvo A; Peligros I; Corcuera A; Belén Rúperez Blanco A; Custodio-Cabello S; López Trabada D; Martín M; DE Ramón E
Anticancer Res; 2018 May; 38(5):3069-3077. PubMed ID: 29715142
[TBL] [Abstract][Full Text] [Related]
10. Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer.
Yoon S; Kang BW; Park SY; Kim HJ; Park JS; Choi GS; Kim JG
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1775-80. PubMed ID: 27339628
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.
Passot G; Chun YS; Kopetz SE; Overman MJ; Conrad C; Aloia TA; Vauthey JN
Eur J Surg Oncol; 2016 Sep; 42(9):1378-84. PubMed ID: 27358198
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
[TBL] [Abstract][Full Text] [Related]
13. Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases.
Stremitzer S; Zhang W; Yang D; Ning Y; Stintzing S; Sebio A; Sunakawa Y; Yamauchi S; Matsusaka S; El-Khoueiry R; Stift J; Wrba F; Gruenberger T; Lenz HJ
Cancer; 2015 Jun; 121(11):1898-905. PubMed ID: 25690670
[TBL] [Abstract][Full Text] [Related]
14. Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.
Kawaguchi Y; Lillemoe HA; Panettieri E; Chun YS; Tzeng CD; Aloia TA; Kopetz S; Vauthey JN
J Am Coll Surg; 2019 Sep; 229(3):286-294.e1. PubMed ID: 31054911
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Impact of Adjuvant Chemotherapy after Hepatic Resection for Synchronous and Early Metachronous Colorectal Liver Metastases.
Nishioka Y; Moriyama J; Matoba S; Kuroyanagi H; Hashimoto M; Shindoh J
Dig Surg; 2018; 35(3):187-195. PubMed ID: 28848205
[TBL] [Abstract][Full Text] [Related]
16. mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival.
Yasuno M; Uetake H; Ishiguro M; Mizunuma N; Komori T; Miyata G; Shiomi A; Kagimura T; Sugihara K
Int J Clin Oncol; 2019 May; 24(5):516-525. PubMed ID: 30612267
[TBL] [Abstract][Full Text] [Related]
17. Microscopic biliary and perineural invasion and clinical outcome after neoadjuvant bevacizumab-based chemotherapy and liver resection in patients with colorectal liver metastases.
Stift J; Graf A; Schwarz C; Tamandl D; Starlinger P; Herac M; Beer A; Wrba F; Bodingbauer M; Kaczirek K; Stremitzer S
Eur J Surg Oncol; 2018 Jan; 44(1):139-147. PubMed ID: 29203074
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases.
Kawamura J; Yazawa T; Sumida K; Kida Y; Ogawa R; Tani M; Kawasoe J; Yamamoto M; Harada H; Yamamoto H; Zaima M
World J Surg Oncol; 2016 Feb; 14():56. PubMed ID: 26911142
[TBL] [Abstract][Full Text] [Related]
19. [Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].
Dede K; Láng I; Pörneczi B; Mester G; Fekete A; Kőszegi G; Mersich T; Besznyák I; Bursics A
Magy Seb; 2013 Dec; 66(6):325-30. PubMed ID: 24333977
[TBL] [Abstract][Full Text] [Related]
20. Host MICA Polymorphism as a Potential Predictive Marker in Response to Chemotherapy for Colorectal Liver Metastases.
Nishioka Y; Shindoh J; Inagaki Y; Gonoi W; Mitsui J; Abe H; Yoshioka R; Yoshida S; Fukayama M; Tsuji S; Hashimoto M; Hasegawa K; Kokudo N
Dig Dis; 2018; 36(6):437-445. PubMed ID: 29969766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
